Retrophin Inc (NASDAQ:RTRX) insider Noah L. Rosenberg sold 750 shares of Retrophin stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $18.59, for a total transaction of $13,942.50. Following the completion of the sale, the insider now owns 29,055 shares in the company, valued at approximately $540,132.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Noah L. Rosenberg also recently made the following trade(s):
- On Tuesday, July 28th, Noah L. Rosenberg sold 870 shares of Retrophin stock. The shares were sold at an average price of $20.49, for a total transaction of $17,826.30.
NASDAQ:RTRX opened at $18.04 on Friday. The company’s 50-day moving average price is $18.85 and its 200-day moving average price is $17.08. The company has a current ratio of 7.23, a quick ratio of 7.14 and a debt-to-equity ratio of 0.66. The company has a market cap of $918.34 million, a P/E ratio of -8.55 and a beta of 0.74. Retrophin Inc has a twelve month low of $8.98 and a twelve month high of $21.92.
Retrophin (NASDAQ:RTRX) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.58) EPS for the quarter, hitting analysts’ consensus estimates of ($0.58). Retrophin had a negative net margin of 49.13% and a negative return on equity of 36.38%. The company had revenue of $48.43 million for the quarter, compared to the consensus estimate of $48.50 million. On average, analysts expect that Retrophin Inc will post -1.65 earnings per share for the current year.
Several brokerages have recently issued reports on RTRX. BMO Capital Markets dropped their target price on shares of Retrophin from $34.00 to $31.00 in a research report on Monday, July 13th. Wedbush began coverage on shares of Retrophin in a research report on Thursday, September 17th. They issued an “outperform” rating and a $33.00 target price on the stock. BTIG Research initiated coverage on shares of Retrophin in a research report on Tuesday, June 16th. They issued a “buy” rating and a $25.00 target price on the stock. Bank of America initiated coverage on shares of Retrophin in a research note on Monday, August 24th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Barclays reissued a “hold” rating and issued a $21.00 price target on shares of Retrophin in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $27.38.
A number of hedge funds have recently modified their holdings of RTRX. SG Americas Securities LLC purchased a new position in Retrophin during the first quarter worth about $122,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Retrophin by 256.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,734 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 5,564 shares during the period. ProShare Advisors LLC purchased a new stake in shares of Retrophin in the 2nd quarter valued at approximately $256,000. AJO LP raised its stake in shares of Retrophin by 97.9% in the 2nd quarter. AJO LP now owns 14,847 shares of the biopharmaceutical company’s stock valued at $303,000 after acquiring an additional 7,343 shares during the period. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Retrophin by 335.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 21,061 shares of the biopharmaceutical company’s stock valued at $307,000 after acquiring an additional 16,228 shares during the period.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Further Reading: What is the FTSE 100 index?
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.